MARKETS
Earnings

Conference Call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $42.000M-$48.000M to $37.000M-$40.000M vs $42.914M Est

Aug 11, 2026 · 04:16 PM ET· updated 1h ago

BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $42.000 million-$48.000 million to $37.000 million-$40.000 million vs $42.914 million estimate.

Share
Why It Matters

BioHarvest said it now expects to make less money next year than it thought before—about $37–40 million instead of $42–48 million. When a company lowers its guess about future sales, it's worth watching to see if they explain why, since it might signal challenges ahead.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.